Dora Cristiana Lima, Alvarez-Silva Marcio, Trentin Andréa Gonçalves, de Faria Tatiany Jovita, Fernandes Daniel, da Costa Robson, Stimamiglio Marco, Lemos-Senna Elenara
Laboratório de Farmacotécnica, Departamento de Ciéncias Farmacéuticas, Centro de Ciéncias da Saúde, Universidade Federal de Santa Catarina, Campus Trindade, Florianópolis, Brazil.
J Pharm Pharm Sci. 2006;9(1):22-31.
The aim of this work was to evaluate the pulmonary antimetastatic activity and the systemic toxicity of camptothecin-loaded microspheres.
PCL microspheres containing camptothecin (CPT) were prepared by the emulsion solvent/evaporation method and characterized according to their encapsulation efficiency, particle size, morphology, and drug release. The ability of CPT to inhibit the lung metastasis was verified using an experimental mouse model intravenously injected with metastatic B16- F10 melanoma cells. The microspheres and the free drug were given intraperitoneally at a dose of 7 mg/kg at intervals of three or five days for 24 days. The systemic toxicity of CPT was evaluated by weight measurements, survival and hemograms of the animals.
The encapsulation efficiency was nearly 80%. The drug release was complete after 72 hours, but the burst effect increased from 7% to 35% with the increase in CPT content in the particles. It was observed during the in vivo essays that all groups treated with CPT had a decrease of nearly 70% in the number of lung metastases. However, systemic toxicity was verified in animals that received the free drug.
Camptothecin-loaded microspheres demonstrated similar therapeutic efficacy when compared to those of the free drug, but the toxicity was significantly reduced.
本研究旨在评估载有喜树碱的微球的肺部抗转移活性和全身毒性。
采用乳液溶剂/蒸发法制备含喜树碱(CPT)的聚己内酯微球,并根据其包封率、粒径、形态和药物释放情况进行表征。使用静脉注射转移性B16-F10黑色素瘤细胞的实验小鼠模型验证CPT抑制肺转移的能力。微球和游离药物以7mg/kg的剂量腹腔注射,每隔三天或五天给药一次,共给药24天。通过测量动物体重、存活率和血常规来评估CPT的全身毒性。
包封率接近80%。72小时后药物释放完全,但随着颗粒中CPT含量的增加,突释效应从7%增加到35%。在体内实验中观察到,所有接受CPT治疗的组肺转移数量减少了近70%。然而,在接受游离药物的动物中证实了全身毒性。
与游离药物相比,载有喜树碱的微球显示出相似的治疗效果,但毒性显著降低。